biOasis Technologies Inc. is a development-stage biopharmaceutical company, which is focused on research, development and commercialization of technologies and products that are intended for the treatment of central nervous system (CNS) diseases and diseases of the brain. The Company researches and develops products for diagnosis and treatment of neurological diseases and disorders. It is engaged in the development of its vectors Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB). The Transcend brain delivery platform exploits the BBB penetrating properties of a recombinant soluble human protein known as melanotransferrin (MTf or p97) and portions thereof. Transcend delivery molecules have the ability to transport a range of molecules across the BBB. The Company owns approximately 30 the United States and foreign patents/applications related to p97 as a BBB delivery vector and as a biomarker for Alzheimer's disease.